MS Speaks

[size=inherit]Sales of Roche’s new multiple sclerosis therapy Ocrevus more than tripled in the first nine months of 2018, helping to compensate for the loss of patent protection on its older blockbuster drugs.[/size][/font]
[size=inherit]Ocrevus[/size][/b][/font][/size] (ocrelizumab) only made its debut in the US last year, but has already vaulted itself to blockbuster status, with sales up 238% to CHF 1.67bn ($1.68bn). Roche said it has seen strong uptake in both relapsing-remitting and primary progressive forms of MS in the US, which still accounts for more than 90% of the drug’s sales, with Europe gaining traction with sales of CHF 130m.